While the use of CLC systems is increasing, data on durable use for >1 year are limited. We present 18-month data on a recently approved CLC system (Control-IQ, Tandem Diabetes Care) in a randomized controlled trial with follow-up extension phase.

The study had 164 participants with T1D (14-71 years old) who for this analysis were divided in 3 groups: Group 1: CLC for 6 months, then continued CLC to study end; Group 2: CLC for 6 months, then PLGS (Basal-IQ) for 3 months, then CLC to study end; and Group 3: SAP for 6 months, then CLC to study end. Data were evaluated in 3-month intervals for the primary outcome of time in range (TIR, 70-180mg/dL) and secondary outcomes of hypoglycemia, hyperglycemia and HbA1c.

Participants in Group 1 maintained significant improvements in TIR over 18 months with overall mean of 69.9% and sustained reductions in HbA1c. TIR improvement was seen within one month of initiation of CLC and retained its durability over 18 months of use. Group 2 had deterioration in time in range and HbA1c when placed on PLGS for 3 months and restored TIR and HbA1c once resuming CLC. Group 3 had persistent improvements in TIR and HbA1c after transitioning from SAP to CLC. There were 4 severe hypoglycemic events (all after month 9) and 4 DKA events. CLC use was generally 90% or higher with no trend toward decreased use over time. Sustained use of CLC over 18 months demonstrated rapid and consistent improvements in TIR, HbA1c, and hypoglycemia.

Disclosure

S.A. Brown: Research Support; Self; Dexcom, Inc., Insulet Corporation, Roche Diabetes Care, Tandem Diabetes Care, Tolerion, Inc. D. Raghinaru: None. B.A. Buckingham: Advisory Panel; Self; ConvaTec Inc., Medtronic. Research Support; Self; Beta Bionics, Inc., Dexcom, Inc., Insulet Corporation, Medtronic, Tandem Diabetes Care. Y.C. Kudva: Research Support; Self; Dexcom, Inc., Roche Diabetes Care. Other Relationship; Self; Abbott. L.M. Laffel: Advisory Panel; Self; Roche Diabetes Care. Consultant; Self; Boehringer Ingelheim Pharmaceuticals, Inc., ConvaTec Inc., Dexcom, Inc., Insulet Corporation, Insulogic LLC, Janssen Pharmaceuticals, Inc., Lilly Diabetes, Novo Nordisk Inc., Sanofi US. C.J. Levy: Consultant; Self; Dexcom, Inc. Employee; Spouse/Partner; Allergan plc. Research Support; Self; Abbott, Dexcom, Inc., Insulet Corporation. J.E. Pinsker: Advisory Panel; Self; Medtronic. Consultant; Self; Eli Lilly and Company, Tandem Diabetes Care. Research Support; Self; Dexcom, Inc., Eli Lilly and Company, Insulet Corporation, Medtronic, Tandem Diabetes Care. Speaker’s Bureau; Self; Tandem Diabetes Care. R. Wadwa: Advisory Panel; Self; Eli Lilly and Company, Medtronic. Research Support; Self; Dexcom, Inc., Eli Lilly and Company, MannKind Corporation, Medtronic, Novo Nordisk Inc., Tandem Diabetes Care. J. Lum: None. C. Kollman: Other Relationship; Self; Dexcom, Inc., Tandem Diabetes Care. R. Beck: None. B. Kovatchev: Advisory Panel; Self; Dexcom, Inc. Research Support; Self; Dexcom, Inc., Tandem Diabetes Care. Speaker’s Bureau; Self; Dexcom, Inc., Sanofi, Tandem Diabetes Care. Other Relationship; Self; Dexcom, Inc., Johnson & Johnson, Sanofi.

Funding

National Institute of Diabetes and Digestive and Kidney Diseases (UC4108483); University of Virginia Strategic Investment Fund (Project 88); Tandem Diabetes Care

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.